双核铜 (II) 复合体与桥接双 (chalcone) 连接体显示出在人体癌细胞上显著的体外细胞毒性和增强的选择性
Zdeněk Trávníček1, Ján Vančo1, Jan Belza1
1Regional Centre of Advanced Technologies and Materials (RCPTM), Czech Advanced Technology and Research Institute (CATRIN), Palacký University, Šlechtitelů 27, 772 00 Olomouc, Czech Republic.
Journal of inorganic biochemistry
|January 12, 2024
概括
新的双核铜 (II) 复合体含有双核基连接体,显示出强大的抗癌活性. 这些复合物诱导癌细胞的细胞循环停止和细胞亡,提供了一个有前途的治疗策略.
科学领域:
- 协调化学 协调化学
- 材料科学 材料科学 材料科学
- 化学生物学 化学生物学
背景情况:
- 双化) 分子在协调化学中充当了多功能桥梁连接体.
- 双核铜 (II) 复合体正在研究其潜在的生物应用.
- 基衍生物已经证明对各种癌症细胞系具有细胞毒性.
研究的目的:
- 通过使用双核) 连接物合成和表征新的双核铜 (II) 复合物.
- 为了评估这些复合物的体外细胞毒性,与人类癌症细胞系的小组进行对比.
- 研究作用机制,包括细胞循环效应,亡诱导和反应性氧物种生成.
主要方法:
- 通过阿尔多尔凝结合成一个双联体 (H2L).
- 使用各种N-捐赠体配体 (phen,bpy,mebpy,bphen,nphen) 制备和表征五种双核铜 (II) 复合体.
- 在体外细胞毒性测试 (IC50测定),流动细胞计 (细胞周期,细胞亡,ROS) 和细胞铜吸收研究.
主要成果:
- 合成的双核铜 (II) 复合体在体外对卵巢,前列腺,骨肉瘤,乳腺和肺癌细胞系 (IC50 ≈ 0.35-7.8 μM) 具有显著的细胞毒性.
- 细胞毒性是时间依赖的,并且观察到细胞吸收铜.
- 在A2780细胞中的机制研究揭示了G2/M细胞周期停止,通过内在途径诱导亡,线粒体损伤和细胞内ROS产生增加.
结论:
- 双核铜 (II) 复合物与桥接双核铜 (II) 连接物显示出强大的抗癌活性.
- 观察到的细胞毒性是通过细胞周期在G2/M阶段的停止和诱导细胞亡的介导.
- 这些发现突显了这些铜复合物的潜力,作为新型化疗剂.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Electron Transport Chain: Complex I and II
13.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.4K


